STOCKHOLM, October 31, 2022 /PRNewswire/ — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotechnology company focused on the discovery and development of therapies for difficult-to-treat hematological diseases, announced today that the number of shares and Oncopeptides votes changed as a result of the Company’s issuance of 3,940,607 new Class C shares pursuant to the Shareholder Program Board SHP 2022 and the Co-Worker LTIP 2022 incentive program resolved by the Annual General Meeting June 28, 2022. Prior to the share issuance, the total number of Oncopeptides shares and votes outstanding was 90,368,660. As a result of the share issuance, the number of Oncopeptides shares outstanding has increased by 3,940,607 shares, representing 394,060.7 votes. Today, the total number of Oncopeptides shares outstanding is 94,309,267 shares, of which 90,368,660 are common shares and 3,940,607 are Class C shares. The number of votes in Oncopeptides today is 90,762,720.7. The share capital has increased by around SEK 437,845.24 from approx SEK 10,040,962.63 until about 10,478,807.87 SEC.
For more information please contact
Annika Muskantor, CFO, Oncopeptides AB (ed.)
E-mail: annika.muskantor@oncopeptides.com
Telephone: +46 70 823 86 91
Rolf GulliksenGlobal Head of Corporate Communications, Oncopeptides AB (ed.)
E-mail: rolf.gulliksen@oncopeptides.com
Telephone: + 46 70 262 96 28
The information in the press release is information that Oncopeptides is required to disclose under the Swedish Trading in Financial Instruments Act. The information was submitted for publication through the mediation of the above contact persons October 31, 2022at 08:00 (CET).
About oncopeptides
Oncopeptides is a global biotechnology company focused on the discovery and development of therapies for intractable hematological diseases. The Company leverages its proprietary Peptide Drug Candidate, PDC, platform to develop compounds that…
